Lineage Cell Therapeutics Stock Performance
| LCTX Stock | USD 0.57 0.06 9.52% |
On a scale of 0 to 100, Lineage Cell holds a performance score of 2. The company secures a Beta (Market Risk) of -1.04, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Lineage Cell are expected to decrease slowly. On the other hand, during market turmoil, Lineage Cell is expected to outperform it slightly. Please check Lineage Cell's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to make a quick decision on whether Lineage Cell's current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lineage Cell Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Lineage Cell showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 3:1 | Last Split Date 1997-10-31 |
1 | Down -43.14 percent in 4 Weeks, Heres Why Lineage Cell Looks Ripe for a Turnaround | 12/17/2024 |
2 | Acquisition by Jill Howe of 10500 shares of Lineage Cell at 0.89 subject to Rule 16b-3 | 01/03/2025 |
3 | Lineage Cell Therapeutics Secures 30M Funding, Extends Runway to 2027 for Cell Therapy Pipeline - StockTitan | 01/06/2025 |
4 | Acquisition by Russell Angus C. of 50000 shares of Lineage Cell subject to Rule 16b-3 | 01/13/2025 |
5 | Acquisition by Mulroy Michael H. of 7000 shares of Lineage Cell at 1.4 subject to Rule 16b-3 | 01/24/2025 |
6 | Acquisition by Broadwood Partners, L.p. of tradable shares of Lineage Cell at 0.91 subject to Rule 16b-3 | 01/27/2025 |
7 | Broadwood Partners acquires 6 million in Lineage Cell Therapeutics shares - Investing.com | 01/28/2025 |
8 | Lineage Cell Therapeutics Earns Buy Rating from HC Wainwright - MarketBeat | 02/04/2025 |
9 | Disposition of 31249 shares by Culley Brian M of Lineage Cell subject to Rule 16b-3 | 02/11/2025 |
10 | Disposition of 12547 shares by Culley Brian M of Lineage Cell at 0.65 subject to Rule 16b-3 | 02/12/2025 |
| Begin Period Cash Flow | 11.9 M |
Lineage |
Lineage Cell Relative Risk vs. Return Landscape
If you would invest 57.00 in Lineage Cell Therapeutics on November 29, 2024 and sell it today you would earn a total of 1.32 from holding Lineage Cell Therapeutics or generate 2.32% return on investment over 90 days. Lineage Cell Therapeutics is currently generating 0.2055% in daily expected returns and assumes 5.8864% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Lineage, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lineage Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lineage Cell Therapeutics, and traders can use it to determine the average amount a Lineage Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0349
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LCTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.89 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Lineage Cell is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lineage Cell by adding it to a well-diversified portfolio.
Lineage Cell Fundamentals Growth
Lineage Stock prices reflect investors' perceptions of the future prospects and financial health of Lineage Cell, and Lineage Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lineage Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (2.31) % | ||||
| Operating Margin | (1.02) % | ||||
| Current Valuation | 113.08 M | ||||
| Shares Outstanding | 228.31 M | ||||
| Price To Earning | 3.62 X | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 16.41 X | ||||
| Revenue | 8.95 M | ||||
| Gross Profit | 11.03 M | ||||
| EBITDA | (24.04 M) | ||||
| Net Income | (21.49 M) | ||||
| Cash And Equivalents | 66.36 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 2.95 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.01 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (28.57 M) | ||||
| Earnings Per Share | (0.10) X | ||||
| Market Capitalization | 143.04 M | ||||
| Total Asset | 101.02 M | ||||
| Retained Earnings | (384.86 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 12.84 M | ||||
| Current Liabilities | 2.74 M | ||||
About Lineage Cell Performance
Evaluating Lineage Cell's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lineage Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lineage Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Lineage Cell Therapeutics performance evaluation
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lineage Cell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lineage Cell had very high historical volatility over the last 90 days | |
| Lineage Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 8.95 M. Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 11.03 M. | |
| Lineage Cell Therapeutics currently holds about 66.36 M in cash with (28.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Lineage Cell has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 12547 shares by Culley Brian M of Lineage Cell at 0.65 subject to Rule 16b-3 |
- Analyzing Lineage Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lineage Cell's stock is overvalued or undervalued compared to its peers.
- Examining Lineage Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lineage Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lineage Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lineage Cell's stock. These opinions can provide insight into Lineage Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.